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A single intraperitoneal injection of  rats with an aqueous suspension of  peptid- 
oglycan-polysaccharide polymers derived from group A streptococci (PG-APS) 1 
or from certain other bacterial species, results in acute joint inflammation that is 
followed by a chronic, recurrent, erosive arthritis (1-4). The histologic and 
radioiogic features of this experimental disease resemble those of human rheu- 
matoid arthritis. The clinical course is characterized by repeated remissions and 
exacerbations, and eventual progression to ankylosis, fibrosis, and loss of  function 
(1, 5). The severity and course of  arthritis is influenced by the sex and genetic 
background of  the rat (3, 6). The persistence of  cell wall in chronically inflammed 
tissues is important in PG-APS-induced arthritis and in the various other animal 
models of  chronic inflammation induced by PG-APS (1, 7-1 1). 
The size of  the PG-APS polymers is important in determining the course and 
severity of  arthritis in the rat model (12, 13). Differential centrifugation of  
sonicated cell wall preparations has been used to obtain families of  PG-APS with 
different average molecular weight and arthropathic potential (12). The smaller 
fragments, which have an average molecular weight of 5.3 x 106, induce a severe 
acute arthritis but relatively little chronic disease. Fragments of  intermediate 
size, with an average molecular weight of 5.0 × 107, cause moderate acute and 
severe chronic arthritis. Recently, it has been demonstrated that PG-APS can be 
degraded in vitro with mutanolysin (M-1), or phage-associated lysin, to fragments 
of  a molecular weight <5.0 x 106. When injected intraperitoneally or intrave- 
nously into rats, these enzymatic digests cannot induce arthritis; however, they 
cause a rapid, transient edema of the limbs (13). 
Mutanolysin is a muramidase derived from Streptomyces globisporus. It has been 
used to digest cell walls from a number of  bacterial species (14-17), since it is 
specific for the ~/ 1-4 linkage of  N-acetyimuramyl-N-acetyl glucosamine in the 
glycan backbone of peptidoglycan. The finding that PG-APS digested in vitro 
with mutanolysin loses its arthropathic potential prompted us to investigate the 
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in vivo effect  o f  this enzyme on PG-APS-induced arthritis. We found that a single 
intravenous injection o f  mutanolysin,  even when given at the peak o f  acute jo int  
inflammation, p reven ted  the deve lopment  o f  recur ren t ,  chronic erosive arthritis. 
Mate r i a l s  a n d  M e t h o d s  
Preparation of Cell Wall. Purified cell walls were prepared from group A, type 3, 
strain D-58 streptococci as previously described (12). Briefly, streptococci were grown in 
Todd Hewitt broth (BBL Microbiology Systems, Cockeysville, MD), harvested, washed in 
sterile phosphate-buffered saline (PBS), and disrupted in a Braun MSK shaker (Bronwill 
Scientific Inc., Rochester, NY). Intact cells were removed by centrifugation at 2,000 g for 
30 min. Cell walls were pelleted by centrifugation at 10,000 g for 30 min and further 
purified by sequential treatment with RNase, trypsin, and papain, followed by chloroform- 
methanol extraction. The cell walls were then washed with water, dialysed against water, 
and lyophilized. The lyophilized cell walls were resuspended to 20 mg/ml in PBS and 
sonicated for 70 min in a Branson sonifier (Branson Sonic Power Co., Danbury, CT) 
using a 1/2 inch probe in a sealed 40-ml stainless steel cup that was cooled with a water 
jacket. The sonicated cell wall was centrifuged at 10,000 g for 30 min, and the supernatant 
collected for injection into rats. 
Mutanolysin Preparations. The purified M-1 fraction of mutanolysin and crude mutan- 
olysin were obtained from K. Yokagawa (Dianippon Pharmaceuticals, Ltd., Osaka, Japan) 
or purchased from Miles Laboratories, Inc., Elkhart, IN. The purity of the mutanolysin 
preparations was tested by analytical isoelectric focusing (IEF) using 5% polyacrylamide 
gels, Servalytes 2-11 (Serva Biochemicais, Heidelberg, Federal Republic of Germany), and 
an LKB multiphor flat-bed apparatus (LKB Produkter, Bromma, Sweden). The protein 
standards were Serva protein test mixture 9 (Serva Biochemicals). When the gels were 
focused at a constant power of 4 W for 2 h, purified mutanolysin showed a single cathodal 
migrating band, while crude mutanolysin showed at least five major bands. When an IEF 
gel was run under the same conditions for 70 min, to avoid gradient drift and to increase 
resolution in the alkaline region of the gel, an additional band was seen in the purified 
mutanolysin preparations (Fig. 1). 
Proteolytic activity has been reported to co-migrate with M-1 on IEF gels, but it can be 
separated from the muramidase by ion exchange chromatography on CM Sephadex, 
which was the procedure involved in the purification of the mutanolysin used in this study 
(14, 15, 18). Proteolytic activity in the mutanolysin preparations was measured using the 
Azocoll assay (Calbiochem-Behring Corp., La Jolla, CA), as described by Siegel et al. (18). 
The purified M-1 preparations had no detectable proteolytic activity, while the crude 
mutanolysin preparation was heavily contaminated. 
Mutanolysin was also purified in our laboratory from crude enzyme by preparative IEF 
in a granulated gel bed (Ultradex; LKB Produkter) on an LKB multiphor flat-bed 
apparatus. The procedure followed LKB application note 198, except that Servalytes 3- 
10 (Serva Biochemicals) were used in place of LKB ampholines. The mutanolysin purified 
by IEF was free of proteolytic activity and possessed the same in vivo effect on PG-APS- 
induced arthritis, when administered immediately after cell wall, as M-1 purified by the 
method of Yokagawa et al. (14, 15). Immediately before injection into rats, mutanolysin 
preparations were solubilized by sonication for 30 s using a 9 kcycle sonic oscillator 
(Raytheon Co., Waltham, MA). 
Animals. Inbred female Lewis rats were obtained from Charles River Breeding Lab- 
oratories, Wilmington, MA. They weighed 100-120 g at the time of PG-APS injection. 
The rats were housed two to three per cage and fed Purina rat chow and water ad libitum. 
Scoring of Edema and Arthritis. Arthritis was scored on an arbitrary scale of 0-4, as 
described previously (1), with a maximum score of 16 per rat. The chronic erosive nature 
of the arthritis was confirmed by x ray (5) and by histological evaluation. The transient 
edema that appeared in the front and hind limbs of rats given M-1 immediately after PG- 
APS was estimated by a visual assessment of swelling over the first 10 h postinjection. An 
arbitrary scale of 0-4 was also used for each limb; therefore, the maximum score per rat 
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Fmu~tE 1. IEF of several mutanolysin preparations. 10-~g samples were applied in the acidic 
region of the gel and allowed to migrate towards the basic region. (A) Protein standards with 
isoelectric points ranging from 3.5 to 10.6. (B) Crude mutanolysin. (C and D) Two different 
purified preparations of mutanolysin. 
was 16. In a previous study (13, 19), using PG-APS digested in vitro with mutanolysin, or 
purified group A polysaccharide, we found an excellent correlation between clinical 
scoring and the accumulation of ~2sI human serum albumin in the limbs. 
Histology. Rat tissues were fixed in 10% formalin, and paraffin sections were stained 
with hematoxylin and eosin (HE) and by periodic acid-Schiff digest method. The tissues 
of the ankles and hind feet were decalcified in formic acid-sodium citrate solution for 5-  
14 d after fixation. Tissue sections from two to eight rats from each group were examined. 
Quantitation of Cell Wall in Tissue Extracts. An enzyme-linked immunosorbent assay 
(ELISA) modification of the solid phase radioimmunoassay developed by Eisenberg et ai. 
(9) was used to quantitate the amount of PG-APS in rat blood, liver, spleen, and limbs. 
Briefly, tissue samples were frozen in liquid nitrogen, crushed, and extracted with 0.2 M 
Tris buffer containing 1% Tween 80 and 5 mg/ml collagenase (Sigma Chemical Co., St. 
Louis, MO) for 6 h at 37 ° C. Supernatants of the extracts were added to 96-well microtiter 
plates previously coated with affinity-purified anti-group A antibody. Biotinylated affinity- 
purified anti-group A antibody was then added, followed by avidin alkaline phosphatase. 
The color reaction was developed using p-nitrophenyl phosphate substrate (Sigma Chem- 
ical Co.) and monitored by an automated Microelisa reader (model MR 580; Dynatech 
Laboratories, Inc., Alexandria, VA). 
Chemical Analysis. Cell wall preparations were analyzed by gas-liquid chromatography. 
N-acetyl-muramic acid, N-acetyl-glucosamine, rhamnose, and glucose were assayed as their 
alditol acetates (20). Samples were hydrolyzed under vacuum for 3 h at 100°C with 2 N 
sulfuric acid before derivatization. Rhamnose was also assayed using the method of Dische 
and Shettles (2 I). 
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Resul ts  
Mutanolysin Can Prevent PG-APS-induced Arthritis. In the initial experiment,  
18 rats were injected intraperitoneally with an arthropathic dose of  PG-APS (20 
#g rhamnose /gram body weight) and immediately thereafter  injected with 0.4 
mg i.v. o f  mutanolysin. A control group of  18 rats was injected intraperitoneally 
with PG-APS followed by 0.4 ml of  PBS i.v. Another  control group of  three rats 
was injected with PBS i.p. and 0.4 mg mutanolysin i.v. The  control group 
injected with PG-APS and PBS developed the typical course of  severe acute and 
chronic arthritis (Fig. 2). In contrast, the rats injected with PG-APS and treated 
with mutanolysin developed a mild acute arthritis that  disappeared within 14 d 
with no subsequent appearance of  inflammation over the period of  observation 
(Fig. 2). The  control group receiving only enzyme displayed no evidence of  
inflammation at any time. 
It is important  to note that  the rats given mutanolysin immediately after PG- 
APS developed a transient limb edema that reached a peak by 2-3  h and subsided 
by 9 h (Fig. 2). This response is identical to that previously reported (13) with 
the injection of  fragments of  PG-APS generated by in vitro digestion with 
mutanolysin. This transient edema did not  develop in either control group. 
A separate experiment  was per formed for the histological evaluation of  rats 
injected with an arthropathic dose o f  PG-APS and immediately thereaf ter  with 
mutanolysin or PBS. The  histological changes observed in the tarsal joints of  
non-enzyme- t rea ted  Lewis rats were similar to the changes previously repor ted 
to occur in Sprague-Dawley rats (1, 2), with the exception that the late destruction 
of  subchondral bone and growth of  new bone was much more extensive in Lewis 
rats. When active mutanolysin was injected immediately after  PG-APS, the initial 
exudative and proliferative synovitis observed 3 d after injection was qualitatively 
similar in the treated and untreated groups (Figs. 3 and 4). At 7 d after injection 
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FIGURE 2. The course of arthritis in rats treated with mutanolysin (M-l) intravenously 
immediately after an intraperitoneal injection of an arthropathic dose of PG-APS. The control 
group received PG-APS i.p. and 0.4 ml of PBS i.v.; the experimental group received PG-APS 
i.p. and 0.4 ml M-1 (1 mg/ml) i.v. There were initially 18 rats in each group. Six rats from 
each group were killed at 2, 5, and 36 d after PG-APS injection for quantitation of cell wall 
in tissues (Table I). Clinical joint scores (arthritis or edema) in this and subsequent figures are 
presented as the mean + SEM. The difference in arthritis scores between groups was significant 
(P < 0.01) at all time points as calculated by the Student's t test. 
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FIGURE 3. Tarsal joint of a control rat that received PG-APS followed immediately by PBS. 
Tissues were collected after 3 d. An acute exudative synovitis was present. The joint space 
contained leukocytes and fibrin. HE stained. × 100. 
the extent  of  the acute synovitis was less in the animals receiving mutanolysin. 
At 14 d after injection of  PG-APS the animals given mutanolysin showed very 
mild synovitis characterized by focal proliferation of  synovial lining cells, focal 
areas o f  scarring in the synovial stroma, and a small number  of  mononuclear  
cells in the synovial tissues. This was in striking contrast to the active synovitis in 
the non-enzyme-t rea ted  control rats. Fig. 5 illustrates a normal-appearing joint  
tissue from an enzyme-treated rat 41 d after  injection of  PG-APS. For contrast, 
the extensive proliferative erosive synovitis observed in the non-enzyme-t rea ted  
animals at 41 d after PG-APS injection is illustrated in Fig. 6. 
PG-APS Arthritis Is Reversed by Mutanolysin When Administered After Acute 
Inflammation Has Been Established. A series of  experiments were performed to 
determine whether  mutanolysin could effect the course of  arthritis after the 
initiation of  disease. In the first experiment,  rats were injected intraperitoneally 
with an arthropathic dose of  PG-APS and randomly divided into two groups. 24 
h later, experimental rats were injected with 0.4 mg of  mutanolysin, and the 
control group received 0.4 ml of  PBS. At the time of  enzyme injection, acute 
arthritis was just  beginning and was relatively mild. Acute arthritis continued to 
develop in enzyme-treated rats, but was significantly less severe than in control 
rats (Fig. 7). Joint  disease resolved in enzyme-treated rats by day 14, and no 
evidence of  recurrence was observed through day 36. Control rats went on to 
develop the typical pat tern of  chronic arthritis. 
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FIGURE 4. Tarsal joint of an experimental rat that received PG-APS followed immediately 
by mutanolysin. Tissues were collected after 3 d. An acute exudative synovitis was present. 
The joint space contained leukocytes and fibrin. HE stained. X 100. 
In a second experiment, rats were injected with mutanolysin or PBS 3 d after 
receiving an arthropathic dose of  cell wall, which is approximately the time of  
peak acute inflammation. Joint disease in the enzyme-treated rats was significantly 
less than in the control group within 48 h after treatment and eventually 
completely resolved (Fig. 8). Thus, mutanolysin can reverse progression of  cell 
wall-induced arthritis even when administration is delayed until severe joint 
disease has developed. 
Mutanolysin and PBS-treated rats described in Fig. 8 were examined histolog- 
ically 83 d after PG-APS injection. Rats injected with PG-APS and 3 d later 
given PBS showed erosive synovitis that had evolved to a stage characterized by 
widespread destruction of  cartilage and bone, extensive growth of  new bone 
with marked distortion of  the normal architecture of  the tarsal bones, severe 
scarring of  the synoviai tissue, and fibrous ankylosis of  many of  the joints. A few 
of the joints in each animal were still involved by an acute exudative and 
proliferative synovitis. Rats injected intraperitoneally with PG-APS and 3 d later 
given mutanolysin intravenously showed minimal active inflammation at 83 d, 
which consisted of  focal areas of  hyperplasia of  synovial lining cells. The only 
indication of  previous erosive synovitis were a few small areas where cartilage 
appeared to be replaced by fibrous tissue at the margin of  the joint surfaces and 
focal areas of  scarring in the synovial stroma. 
In a third experiment, mutanolysin or PBS was administered to rats 14 d after 
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FIGURE 5. Tarsal joint of an experimental rat that received PG-APS followed immediately 
by mutanolysin. Tissues were collected after 41 d. The joint space contained no exudate and 
the cartilage was intact. HE stained. × 100. 
PG-APS injection, which is the approximate time when the chronic phase of  
arthritis begins. After a slight initial increase, joint scores of  mutanolysin-treated 
rats declined, and became significantly lower (P < 0.01) than those of  PBS- 
treated rats by day 30 after PG-APS injection (Fig. 9). Fig. 10 illustrates the 
difference in clinical appearance between treated and untreated rats on day 44. 
Subsequently, only three of the nine mutanolysin-treated rats demonstrated a 
recurrent episode of  chronic joint disease. In two of these three rats, the 
exacerbation was mild and short-lived. The third rat with recurrent arthritis 
developed severe joint disease that lasted from day 80 to the end of  the 
experiment (day 127). 
A histological study was performed on day 127 on the rats whose clinical scores 
are shown in Fig. 9. Despite the clinical improvement in the enzyme-treated rats, 
erosive synovitis that had resulted in synovial scarring and extensive distortion 
of  the architecture of  the tarsal bones by abnormal bone growth was equal to 
that of  PBS controls. This was not surprising, however, since by the time enzyme 
was administered 14 d after PG-APS, the rats had proceeded through the acute 
phase of  arthritis. Acute exudative, proliferative, and active erosive synovitis was 
observed in three of the enzyme-treated group and four of  the untreated group 
at 127 d. 
Radiographic Data Confirms Clinical Assessment of Arthritis. Rats injected with 
PG-APS and treated with mutanolysin or PBS at 0, 3, or 14 d after cell wall 
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FIGURE 6. Tarsal jo in t  o f  a control  rat  that  received PG-APS followed immediately by PBS. 
Tissues were collected after  41 d. Extensive erosion o f  cartilage and subchondral  bone was 
present.  HE stained, x 100. 
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FIGURE 7. Effect o f  mutanolysin given 24 h after PG-APS on development  o f  acute and 
chronic arthritis. Two groups o f  six rats were injected intraperitoneally with an ar thropathic  
dose o f  PG-APS followed 24 h later by an intravenous injection o f  PBS (O) or  0.4 mg o f  M-I 
i.v. (@). Statistically significant differences (P < 0.05) between the groups were found at all 
t ime points af ter  administration o f  M- 1. 
injection were x-rayed shortly before the termination of  each experiment. Rats 
treated with mutanolysin up to 3 d after PG-APS injection showed no chronic 
erosive arthritis, while PBS-treated rats displayed the destructive changes asso- 
ciated with chronic erosive synovitis (5). Those rats that were treated with 
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FIGURE 8. Effect of mutanolysin given at the peak of acute arthritis on the further devel- 
opment of  disease. Three groups of  five rats were injected with an arthropathic dose of  PG- 
APS i.p. on day 0 plus 0.4 ml PBS on day 3 (0); 0.4 mg of  M-1 on day 3 (7); or 0.4 mg of  
heat-inactivated M-1 on day 0 (O). Statistically significant differences (P < 0.02) between PBS- 
treated and M-l-treated rats were seen at all time points after day 5. The differences between 
PBS-treated rats and those treated with heat-inactivated M-1 were not significant at any time. 
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FIGURE 9 .  Effect of mutanolysin given 14 d after PG-APS on the development of chronic 
arthritis. A control group of eight rats (e) was given an arthropathic dose of PG-APS i.p. 
followed 14 d later by an injection of PBS i.v. The  experimental group (O) contained nine rats 
that were injected with an arthropathic dose of PG-APS i.p. and 14 d later given 0.4 mg of 
M-1 i.v. 
mutanolysin 14 d after PG-APS and still developed clinical and histological 
arthritis also showed evidence o f  arthritis on x ray. 
Muramidase Activity for Streptococcal Cell Wall Is Required to Modify PG-APS- 
induced Arthritis. As part  o f  the exper iment  in which mutanolysin was given to 
rats 3 d after PG-APS, 0.4 mg of  heat-inactivated mutanolysin (boiled for 10 
min) was injected intravenously into a group of  rats immediately after the 
administration of  an ar thropathic  dose o f  PG-APS. The  results presented in Fig. 
8 demonstra te  that heat-inactivated M-1 does not reduce PG-APS arthritis. 
FIGURE 10. (A) Hind limbs o f  a rat  with PG-APS-induced arthrit is 44 d after PG-APS 
injection. This  rat  had a clinical  score o f  8 and is f rom the control  g roup  (PBS treated) 
descr ibed in Fig. 9. (B) Hind  limbs o f  a mutanolysin-treated rat  44 d af ter  PG-APS injection 
as described for the  exper imental  g roup  in Fig. 9. This  rat had a clinical score o f  0. 
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Histological examination confirmed that heat-inactivated mutanolysin had no 
effect on the development of erosive synovitis. 
An additional control experiment was performed to determine if hen egg 
lysozyme injected in vivo could effect PG-APS-induced arthritis. Hen egg lyso- 
zyme is a basic protein with muramidase activity, but it is unable to degrade 
group A streptococcal cell wall in vitro (22-24). Rats were injected intraperito- 
neally with an arthropathic dose of PG-APS and randomly divided into two 
groups. The control group was treated with 0.4 mi of PBS i.v., while the 
experimental group received 0.4 mg of hen egg lysozyme i.v. The results shown 
in Fig. 11 demonstrate that treatment of cell wall-injected rats in vivo with 
iysozyme does not effect the course of  arthritis. 
Mutanolysin Can Effect the PG-APS-induced Inflammatory Reaction in Other 
Tissues. A histological study of the liver, spleen, and mediastinal lymph nodes 
was performed on all rats whose joint histology was described above. Rats injected 
with PG-APS and not treated with enzyme developed granulomatous lesions in 
the liver, spleen, and mediastinal lymph nodes. The process was extensive in the 
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FIGURE 11. Course of arthritis in rats treated with lysozyme intravenously immediately after 
receiving PG-APS. Two groups of six rats were injected with an arthropathic dose of PG-APS 
i.p. followed immediately by 0.4 ml PBS i.v. (6) or 0.4 nag hen egg lysoz.yme i.v. (O). The 
differences between the two groups were not statistically significant at any ume. 
TABLE I 
Effect of Mutanolysin on the Distribution of Cell Wall in Rat Tissue 
Control (cell wall i.p. plus PBS i.v.) Experimental (cell wall i.p. plus M-1 i.v.) 
Day 2 Day 5 Day 36 Day 2 Day 5 Day 36 
Hind Limbs 0.70 + 0.21" 0.32 + 0.19 0.08 ± 0.06 3.7 ± 1.7 0.86 :t= 0.13 0.19 :!: 0.07 
Spleen 1 0 7 ± 4 1  2 4 5 + 2 9  3 3 ± 1 1  1 6 6 + 4 9  9 2 ± 2 5  1 6 ±  1.7 
Liver 1 4 5 + 2 5  3 2 ± 1 1  ND* 3 0 0 ± 1 8 9  136:t=37 3 9 ± 2 4  
Blood 1 .7±0 .68  0 . 1 1 ± 0 . 0 9  0 .07±0 .01  2 . 3 ± 0 . 9 4  0 .30+0 .07  <0.06 
* Mean + SEM of PG-APS in micrograms per gram of tissue; five rats per group. 
No data. 
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14. The initial reaction appeared to be the formation of  granulomas consisting 
of  focal collection of macrophages and giant cells associated with the presence of 
small numbers of neutrophils and lymphocytes. As the collection of inflammatory 
cells increased in size, the relative number of neutrophils increased in the central 
areas of the lesions and irregular areas of  necrosis developed that became 
surrounded by concentric layers of  fibrous tissue infiltrated with neutrophils and 
mononuclear cells. In contrast, no such changes were observed in rats treated 
with active mutanolysin immediately or 3 d after PG-APS injection. Granuloma- 
tous lesions did develop in rats treated with mutanolysin 14 d after PG-APS 
injection. A more detailed description of the histology of this complex inflam- 
matory response and its relationship to the distribution and persistence of  PG- 
APS in the reticuloendothelial tissues of Lewis rats will be reported elsewhere. 
Mutanolysin Treatment Does Not Cause Elimination of PG-APS from the Tis- 
sue. The quantitative distribution of cell wall in rats injected intraperitoneally 
with PG-APS and immediately injected intravenously with PBS or mutanolysin 
is shown in Table I. The rats for this experiment are those whose course of 
arthritis is shown in Fig. 2. On day 2, 5, and 36, rats were sacrificed for assay. 
The hind limbs, liver, spleen, and blood from enzyme-treated animals contained 
quantities of  PG-APS that equaled or appeared to exceed the amounts found in 
PBS-treated control rats. Therefore,  it is unlikely that mutanolysin causes a rapid 
elimination of  PG-APS from the limbs, liver, and spleen. 
Discussion 
The intravenous injection of a single dose of 0.4 mg of the muralytic enzyme 
mutanolysin profoundly altered the course and severity of PG-APS-induced 
arthritis, even when the enzyme was given after the inflammation was well 
established. In rats that received mutanolysin up to 3 d after PG-APS, acute joint 
inflammation resolved and did not progress into chronic recurrent disease. If  
treatment with the enzyme was delayed until 14 d after PG-APS, the severity of 
the recurrent chronic phase of arthritis was significantly reduced by clinical and 
radiological assessment, although active inflammation was evident in some spec- 
imens by histological examination. 
We originally hypothesized that the mutanolysin would hasten clearance of 
tissue-bound PG-APS. However, quantitative ELISA studies on tissue extracts 
failed to demonstrate that catabolism of PG-APS was significantly enhanced by 
enzyme treatment. In fact, more PG-APS was detected in the tissues of enzyme- 
treated rats than in PBS-treated control animals. This difference could be 
accounted for by increased antibody binding of the enzyme-digested PG-APS in 
the ELISA assay due to the exposure of more epitopes. This was suggested by 
in vitro digestion of PG-APS with mutanolysin, which resulted in enhanced 
ELISA detectability of the same degree as seen in Table I (unpublished obser- 
vations). 
An alternative hypothesis is that mutanolysin modifies cell wall-induced ar- 
thritis by degrading PG-APS to polymers that still persist in tissue, but are of a 
size which is nonarthropathic. Previous studies (12, 13) have demonstrated that 
the polymer size of PG-APS is important for the production of chronic inflam- 
mation. PG-APS degraded in vitro with mutanolysin to fragments with a molec- 
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ular weight of  <5.0 x 106 was unable to induce arthritis by systemic injection 
(13). 
The evidence that PG-APS was degraded in vivo by mutanolysin consists of  
two observations: (a) Rats injected intravenously with mutanolysin immediately 
after an intraperitoneal injection of  PG-APS developed a rapid transient edema 
in their limbs. The kinetics of  edema development was the same as that seen in 
rats injected with PG-APS degraded to a small fragment size by mutanolysin in 
vitro (13). (b) ELISA analysis of  sucrose gradient fractions has shown that the 
proportion of small cell wall fragments in the tissues of  mutanolysin-treated rats 
was greatly increased compared with PBS-treated animals (Janusz, M.J.,  R. A. 
Eisenberg, and J. H. Schwab, manuscript in preparation). 
An extension of our current hypothesis regarding the reduction of PG-APS- 
induced arthritis by mutanolysin is that digested PG-APS fragments could 
interfere with the larger arthropathic cell wall fragments. For example, small 
nonarthropathic PG-APS fragments may compete with arthropathic PG-APS for 
binding sites on synovial tissue or soluble proteins such as complement. This 
hypothesis is attractive, as it would require only a small percentage of the total 
cell wall injected to be degraded to small fragments in order to suppress arthritis. 
Also pertinent is recent work (25) demonstrating that muramyl dipeptide (MDP) 
has antiinflammatory activity in several models of acute inflammation in rats and 
mice. 
It is conceivable that the effect of  mutanolysin on PG-APS-induced arthritis is 
not.due to its specific enzymatic activity. However, heat-inactivated mutanolysin 
did not reduce the severity of arthritis in PG-APS-injected rats. In addition, hen 
egg lysozyme, which is a cationic muralytic enzyme but is unable to digest the 
cell wall of  group A streptococci, did not reduce PG-APS-induced arthritis. In 
another model of  chronic intermittent inflammation, enzymes have been shown 
to mediate in vivo suppression of activity. For example (26), incubation of group 
A cell wall in vitro with the culture supernatant of  Streptomyces albus results in 
digestion of the cell wall and a loss of the ability to produce dermal lesions in 
rabbit skin. In addition, injection of filtrates ofS. albus or group C streptococcal 
phage-associated lysin directly into a cell wall injection site in rabbit skin results 
in a decrease in the severity and duration of dermal lesions (27). 
The demonstration that mutanolysin has a profound effect in vivo on PG-APS- 
induced arthritis may be significant for the study of inflammation, since it 
provides a unique situation in which the phlogistic agent can be rapidly and 
specifically inactivated in vivo while the inflammatory response is evolving. The 
immediate usefulness of mutanolysin is as a tool to dissect various aspects of  PG- 
APS-induced arthritis in the rat. If the model of  cell wall-induced arthritis proves 
to be related to human arthritides, this approach may also be useful in the 
analysis of  the etiology and mechanisms of joint destruction, or even as a 
therapeutic modality. 
S u m m a r y  
A single intravenous injection into rats of  0.4 mg of the muralytic enzyme 
mutanolysin, given as long as 3 d after an arthropathic dose of peptidoglycan- 
polysaccharide polymers derived from group A streptococci (PG-APS), resulted 
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in a complete resolution of  acute arthritis and the prevention of  chronic joint  
disease. When administration of  mutanolysin was delayed until 14 d after the 
injection of  PG-APS, a great reduction in the severity o f  chronic inflammation 
was still observed. Quanti tat ion of  the amount  of  PG-APS present in the limbs, 
spleen, and liver by a solid phase enzyme-linked immunoassay indicated that the 
tissues of  mutanolysin-treated rats contained as much PG-APS as tissues of  PBS- 
treated control rats. In addition, rats t reated with mutanolysin immediately af ter  
receiving an intraperitoneal injection of  PG-APS developed a transient limb 
edema similar to that seen in rats after  the injection o f  PG-APS digested to a 
small f ragment  size in vitro with mutanolysin. We hypothesize that mutanolysin 
acts in vivo by degrading PG-APS to small fragments that persist but are no 
longer arthropathic.  
Received for publication lO July 1984. 
R e f e r e n c e s  
1. Cromartie, W. J., J. G. Craddock, J. H. Schwab, S. K. Anderle, and C. Yang. 1977. 
Arthritis in rats after systemic injection of streptococcal cells or cell walls. J. Exp. 
Med. 146:1585. 
2. Dalldorf, F. G., W.J. Cromartie, S. K. Anderle, R. L. Clark, andJ. H. Schwab. 1980. 
The relation of experimental arthritis to the distribution of streptococcal cell wall 
fragments. Am. J. Pathol. 100:383. 
3. Wilder, R. L., G. B. Calandra, A.J. Garvin, K. D. Wright, and C. T. Hansen. 1982. 
Strain and sex variation in the susceptibility to streptococcal cell wall-induced polyar- 
tbritis in the rat. Arthritis Rheum. 25:1064. 
4. Spitznagel, J. K., K. J. Goodrum, and D. J. Warejcka. 1983. Rat arthritis due to 
whole group B streptococci. Clinical and histopathologic features compared with 
groups A and D. Am.J. Pathol. 112:37. 
5. Clark, R. L.,J. T. Cuttino, S. K. Anderle, W.J. Cromartie, andJ. H. Schwab. 1979. 
Radiologic analysis of arthritis in rats after systemic injection of streptococcal cell 
walls. Arthritis Rheum. 22:25. 
6. Anderle, S. K., J. J. Greenblatt, W.J. Cromartie, R. Clark, and J. H. Schwab. 1979. 
Modulation of the susceptibility of inbred and outbred rats to arthritis induced by 
cells walls of group A streptococci. Infect. lmmun. 25:484. 
7. Wilder, R., J. B. Allen, L. M. Wahl, G. B. Calandra, and S. M. Wahl. 1983. The 
pathogenesis of group A streptococcal cell well-induced polyarthritis in the rat. 
Comparative studies in arthritis-resistant and susceptible inbred rat strains. Arthritis 
Rheum. 26:1442. 
8. Schwab, J. H., w.J .  Cromartie, S. H. Ohanian, andJ. G. Craddock. 1967. Association 
of experimental chronic arthritis with the persistence of group A streptococcal cell 
walls in the articular tissue. J. Bacteriol. 94:1728. 
9. Eisenberg, R., A. Fox, J. J. Greenblatt, S. K. Anderle, W. J. Cromartie, and J. H. 
Schwab. 1982. Measurement of bacterial cell wall in tissues by solid-phase radioim- 
munoassay: correlation of distribution and persistence with experimental arthritis in 
rats. Infect. Immun. 38:127. 
10. Ohanian, S. H., and J. H. Schwab. 1967. Persistence of group A streptococcal cell 
wall related to chronic inflammation of rabbit dermal connective tissue. J. Exp. Med. 
125:1137. 
1374 TREATMENT OF ARTHRITIS IN RATS WITH MUTANOLYSIN 
11. Ohanian, S. H., J. H. Schwab, and W. J. Cromartie. 1969. Relation of rheumatic-like 
cardiac lesions of the mouse to localization of group A streptococcal cell wail. J. Exp. 
Med. 129:37. 
12. Fox, A., R. R. Brown, S. K. Anderle, C. Chetty, W.J. Cromartie, H. Gooder, and J. 
H. Schwab. 1982. Arthropathic properties related to the molecular weight of peptid- 
oglycan-polysaccharide polymers of streptococcal cell walls. Infect. Immun. 35:1003. 
13. Chetty, C., D. G. Klapper, and J. H. Schwab. 1982. Soluble peptidoglycan-polysac- 
charide fragments of the bacterial cell wall induce acute inflammation. Infect. Immun. 
38:1010. 
14. Yokogawa, K., S. Kawata, S. Nishimura, Y. Iheda, and Y. Yoshimura. 1974. Mutan- 
olysin, bacteriolytic agent for cariogenic streptococci: partial purification and prop- 
erties. Antimicrob. Agents Chemother. 6:156. 
15. Yokogawa, K., S. Kawata, T. Takemura, and Y. Yoshimura. 1975. Purification and 
properties of lytic enzymes from Streptomyces globisporus 1829. Agric. Biol. Chem. 
39:1533. 
16. Hamada, S., M. Torri, S. Kotani, N. Masuda, T. Ooshima, K. Yokogawa, and S. 
Kawata. 1978. Lysis of Streptococcus mutans cells with mutanolysin, a lytic enzyme 
prepared from a culture liquor of Streptomyces globisporus 1829. Arch. Oral. Biol. 
23:543. 
17. Calandra, G. B., and R. M. Dole. 1980. Lysis and protoplast formation of group B 
streptococci by mutanolysin. Infect. Immunol. 28:1033. 
18. Siegel, J., S. Hurst, E. Liberman, S. Coleman, and A. Bleweis. 1981. Mutanolysin- 
induced spheroplasts of Streptococcus mutans are true protoplasts. Infect. lmmun. 
31:808. 
19. Chetty, C., R. R. Brown, andJ. H. Schwab. 1983. Edema-producing activity of group 
A streptococcal polysaccharide and its possible role in the pathogenesis of cell wall- 
induced polyarthritis. J. Exp. Med. 157:1089. 
20. Sawardeker, J. S., J. H. SIoneker, and A. Jeanes. 1965. Quantitative determination 
of monosaccharides as their alditol acetates by gas liquid chromatography. Anal. 
Chem. 37:1602. 
21. Dische, A., and L. B. Shettles. 1948. A specific color reaction of methyl pentose and 
a spectrophotometric micromethod for their determination. J. Biol. Chem. 175:595. 
22. Coleman, S. E., I. van de Rijn, and A. S. Bleiweis. 1970. Lysis of grouped and 
ungrouped streptococci by lysozyme. Infect. Immun. 2:563. 
23. Glick, A. D., J. M. Ranhand, and R. M. Cole. 1972. Degradation of group A 
streptococcal cell walls by egg-white lysozyme and human lysosomal enzyme. Infect. 
Immun. 6:403. 
24. Gallis, H. A., S. E. Miller, and R. W. Wheat. 1976. Degradation of 14C-labeled 
streptococcal cell walls by egg white lysozyme and lysosomal enzymes. Infect. Immun. 
13:1459. 
25. Zidek, Z., K. Masek, and F. Sedivy. 1984. Anti-inflammatory effects of muramyl 
dipeptide in experimental models of acute inflammation. Agents Actions. 14:72. 
26. Roberson, B. S., J. H. Schwab, and W. J. Cromartie. 1960. Relation of particle size 
of C polysaccharide complexes of group A streptococci to toxic effects on connective 
tissue.J. Exp. Med. 112:751. 
27. Schwab, J. H. 1962. Analysis of the experimental lesion of connective tissue provided 
by a complex of C polysaccharide from group A streptococci. I. In vivo reaction 
between tissue and toxin.J. Exp. Med. 116:17. 
